San Diego-based mostly Viking Therapeutics marked alone as a serious competitor within the weight loss drug market in February just after revealing promising details from the mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection and in March the company unveil